Regulation - Zelboraf

Filter

Current filters:

Zelboraf

Popular Filters

IQWiG view on Roche’s Zelboraf unchanged despite new data

IQWiG view on Roche’s Zelboraf unchanged despite new data

18-12-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has reassessed Swiss drug major…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments

01-11-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya

11-09-2012

Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…

EuropeGilenyaHealthcareNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRocheZelboraf

UK's NICE delays decision on Roche's Zelboraf, asking for more information

10-08-2012

UK health care watchdog the National Institute for Health and Clinical Excellence (NICE) today (August…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

UK's NICE denies NHS access to Roche melanoma drug Zelboraf

15-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

European approval for Roche skin cancer drug Zelboraf

21-02-2012

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib)…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

EMA recommends approval of Roche’s Zelboraf

19-12-2011

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Parexel

Parexel

Back to top